clinical glutathione Glutathione™ Clinical Glutathione™

Most of the evidence supporting BPC-157 comes from preclinical laboratory and animal research

Some studies have suggested that excluding participants who had gastroenteritis prior to the first use of PPIs or correcting for confounding factors, such as susceptibility and time dependence of bacterial gastrointestinal infections, can remarkably reduce the association between PPI treatment and bacterial gastroenteritis ( Diseases caused by fungal infections of the digestive system have also been linked to the use of PPIs, particularly Candida infections (Mottaghi et al., 2021)

[43] It demonstrated effectiveness and safety for the treatment of the condition in extensive, large-scale clinical trials, [8] and was approved for this indication in Russia under the brand name Ladasten sometime around 2009

It is a prescription medicine, administered by qualified medical practitioners following clinical guidelines